Biological Maturation, Athletic Performance, and Injury Risk in Adolescent Male Soccer Players
NCT07920146, Completed, Alanya Alaaddin Keykubat University
Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Biological Maturation, Athletic Performance, and Injury Risk in Adolescent Male Soccer Players | ClinicalTrials.gov |
| NCT number | NCT07920146 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Enrollment | 106 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Alanya Alaaddin Keykubat University | ClinicalTrials.gov |
| Conditions | Maturation Level, Football Players, Injuries; Muscle, Nontraumatic, Prevention, Performance | ClinicalTrials.gov |
| Interventions | Anthropometric and Performance Assessment. | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-05 | ClinicalTrials.gov |
Registered outcomes 16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Estimated Maturity Offset | Baseline | Biological maturation was estimated using the male-specific Mirwald maturity-offset equation based on decimal chronological age, standing height, sitting height, derived leg length, and body mass. Decimal chronological age was calculated using May 1, 2025 as the common reference date. The outcome was estimated time from peak height velocity (PHV), expressed in years. Negative values indicate time before estimated PHV and positive values indicate time after estimated PHV. This measure is an anthropometric estimate of maturation rather than a direct measurement of biological age. | ClinicalTrials.gov |
| Primary | Functional Movement Screen Total Score | Baseline | Functional movement quality was assessed using the Functional Movement Screen (FMS). Seven movement patterns were scored from 0 to 3: deep squat, hurdle step, in-line lunge, shoulder mobility, active straight-leg raise, trunk stability push-up, and rotary stability. A score of 3 indicates performance meeting the standard criteria, 2 indicates compensatory movement, 1 indicates inability to meet the criteria, and 0 indicates pain. For bilateral items, the lower of the two side scores contributed to the total. The seven item scores were summed to give a total score from 0 to 21 points. Higher scores indicate better functional movement quality. | ClinicalTrials.gov |
| Primary | Final Running Speed in the 30-15 Intermittent Fitness Test | Baseline | Intermittent running performance was assessed using the 30-15 Intermittent Fitness Test on a 40-m shuttle course. The test consisted of 30-second running stages separated by 15-second recovery periods. Running speed started at 8 km/h and increased by 0.5 km/h at each stage. Participants followed audio signals until they could no longer maintain the required pace or continue the test. The outcome was the speed of the last completed stage, recorded in kilometers per hour (km/h). Higher values indicate better intermittent running performance. | ClinicalTrials.gov |
| Primary | Pro-Agility Test Completion Time | Baseline | Change-of-direction performance was assessed using the Pro-Agility Test. Markers were placed 5 yards (4.57 m) to either side of the central starting line. From the central line, the participant moved to and touched the right marker, then the left marker, and returned through the central line. Completion time was measured using a photocell timing system at the central line and recorded in seconds. Lower values indicate faster completion and better change-of-direction performance. | ClinicalTrials.gov |
| Primary | Hamstring Isometric Strength | Baseline | Hamstring isometric strength was assessed using an Active Force 2 digital handheld dynamometer. The participant lay prone with the knee flexed to approximately 90 degrees and performed three maximal isometric knee-flexion contractions lasting approximately 3 to 5 seconds each, with 30 seconds of rest between trials. The highest force recorded across the three trials was used as the outcome and expressed in newtons (N). Higher values indicate greater hamstring isometric strength. | ClinicalTrials.gov |
| Primary | Quadriceps Isometric Strength | Baseline | Quadriceps isometric strength was assessed using an Active Force 2 digital handheld dynamometer. The participant sat with the hip and knee flexed to approximately 90 degrees and performed three maximal isometric knee-extension contractions lasting approximately 3 to 5 seconds each, with 30 seconds of rest between trials. The highest force recorded across the three trials was used as the outcome and expressed in newtons (N). Higher values indicate greater quadriceps isometric strength. | ClinicalTrials.gov |
| Primary | Number of Balance Errors in the Flamingo Balance Test | Baseline | Static balance was assessed using the Flamingo Balance Test. The participant maintained a single-leg stance for \[CONFIRMED TEST DURATION\]. Touching the ground with the non-supporting foot, moving the supporting foot, or losing balance was counted as an error. The total number of balance errors during the assessment was recorded as a count. Lower values indicate better static balance. | ClinicalTrials.gov |
| Primary | Mean Seated Medicine Ball Chest Pass Distance | Baseline | Upper-body explosive performance was assessed using a seated chest pass with a 3-kg medicine ball. The participant sat with the knees extended and the back, shoulders, and head against a wall. The ball was thrown as far as possible from chest level using both hands while maintaining contact with the wall. After warm-up and practice attempts, four valid throws were performed with 30 to 45 seconds of rest between throws. The arithmetic mean of the four throwing distances was recorded in meters (m). Higher values indicate better throwing performance. | ClinicalTrials.gov |
| Primary | Right Anterior Normalized Reach Score on the Y Balance Test | Baseline | Dynamic balance was assessed using the Y Balance Test with the right leg as the stance limb. After practice attempts, three valid reaches were recorded in the anterior direction. The greatest valid reach distance was divided by the length of the right lower limb and multiplied by 100. Lower-limb length was measured from the anterior superior iliac spine to the medial malleolus. The outcome was expressed as a percentage of limb length. Higher values indicate greater reach relative to limb length. | ClinicalTrials.gov |
| Primary | Right Posteromedial Normalized Reach Score on the Y Balance Test | Baseline | Dynamic balance was assessed using the Y Balance Test with the right leg as the stance limb. After practice attempts, three valid reaches were recorded in the posteromedial direction. The greatest valid reach distance was divided by the length of the right lower limb and multiplied by 100. Lower-limb length was measured from the anterior superior iliac spine to the medial malleolus. The outcome was expressed as a percentage of limb length. Higher values indicate greater reach relative to limb length. | ClinicalTrials.gov |
| Primary | Right Posterolateral Normalized Reach Score on the Y Balance Test | Baseline | Dynamic balance was assessed using the Y Balance Test with the right leg as the stance limb. After practice attempts, three valid reaches were recorded in the posterolateral direction. The greatest valid reach distance was divided by the length of the right lower limb and multiplied by 100. Lower-limb length was measured from the anterior superior iliac spine to the medial malleolus. The outcome was expressed as a percentage of limb length. Higher values indicate greater reach relative to limb length. | ClinicalTrials.gov |
| Primary | Right Composite Score on the Y Balance Test | Baseline | Dynamic balance was assessed using the Y Balance Test with the right leg as the stance limb. The greatest valid reach distance from three trials in each of the anterior, posteromedial, and posterolateral directions was used. The three distances were summed, divided by three times the length of the right lower limb, and multiplied by 100. Lower-limb length was measured from the anterior superior iliac spine to the medial malleolus. The composite score was expressed as a percentage of limb length. Higher values indicate greater overall reach relative to limb length. | ClinicalTrials.gov |
| Primary | Left Anterior Normalized Reach Score on the Y Balance Test | Baseline | Dynamic balance was assessed using the Y Balance Test with the left leg as the stance limb. After practice attempts, three valid reaches were recorded in the anterior direction. The greatest valid reach distance was divided by the length of the left lower limb and multiplied by 100. Lower-limb length was measured from the anterior superior iliac spine to the medial malleolus. The outcome was expressed as a percentage of limb length. Higher values indicate greater reach relative to limb length. | ClinicalTrials.gov |
| Primary | Left Posteromedial Normalized Reach Score on the Y Balance Test | Baseline | Dynamic balance was assessed using the Y Balance Test with the left leg as the stance limb. After practice attempts, three valid reaches were recorded in the posteromedial direction. The greatest valid reach distance was divided by the length of the left lower limb and multiplied by 100. Lower-limb length was measured from the anterior superior iliac spine to the medial malleolus. The outcome was expressed as a percentage of limb length. Higher values indicate greater reach relative to limb length. | ClinicalTrials.gov |
| Primary | Left Posterolateral Normalized Reach Score on the Y Balance Test | Baseline | Dynamic balance was assessed using the Y Balance Test with the left leg as the stance limb. After practice attempts, three valid reaches were recorded in the posterolateral direction. The greatest valid reach distance was divided by the length of the left lower limb and multiplied by 100. Lower-limb length was measured from the anterior superior iliac spine to the medial malleolus. The outcome was expressed as a percentage of limb length. Higher values indicate greater reach relative to limb length. | ClinicalTrials.gov |
| Primary | Left Composite Score on the Y Balance Test | Baseline | Dynamic balance was assessed using the Y Balance Test with the left leg as the stance limb. The greatest valid reach distance from three trials in each of the anterior, posteromedial, and posterolateral directions was used. The three distances were summed, divided by three times the length of the left lower limb, and multiplied by 100. Lower-limb length was measured from the anterior superior iliac spine to the medial malleolus. The composite score was expressed as a percentage of limb length. Higher values indicate greater overall reach relative to limb length. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)